Parkinson's disease medication precautions

There is no absolute fixed pattern for the treatment of Parkinson's disease, because the symptoms of different patients may be different, the sensitivity to treatment also varies, the needs of different patients for treatment are different, and the needs of the same patient for treatment at different stages of the disease are also different. Therefore, this guideline may be applicable to general rules. When it is used in actual clinical practice, it is necessary to pay attention to a detailed understanding of the patient's condition (disease severity, symptom type, etc.), treatment response (whether it is effective, onset time, duration of effect, extension of the "on" period of treatment and shortening of the "off" period, whether there are adverse reactions or complications), etc., combined with your own treatment experience, both follow the guidelines and embody the principle of individualization, in order to achieve a more ideal treatment effect.

Appendix: Application and precautions of anti-Parkinson's disease drugs (Table 1)

At present, the anti-Parkinson's disease drugs that have been marketed at home and abroad mainly include dopaminergic drugs and non-dopaminergic drugs. Dopaminergic drugs include: compound levodopa, DAs, MAO-BI, COMTI, and non-dopaminergic drugs include: anticholinergic drugs, antiglutamatergic drugs and adenosine A2 receptor antagonists.

In the process of using anti-Parkinson's disease drugs, it is necessary to balance the efficacy and adverse reactions. In principle, it should start with a small dose and gradually increase the dose until a satisfactory effect is achieved without adverse reactions; each patient has different sensitivity to drug treatment, and attention should be paid to the individualization of dosage and response.